Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Head & Neck 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1Classical hematology 1Breast 1

Conditions

Leukemia, Myeloid, Acute 985Leukemia 733Leukemia, Lymphocytic, Chronic, B-Cell 665Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Myelodysplastic Syndromes 502Lymphoma 340Leukemia, Myelogenous, Chronic, BCR-ABL Positive 308Lymphoma, Non-Hodgkin 294Hematologic Neoplasms 257Lymphoma, Follicular 223Multiple Myeloma 213Burkitt Lymphoma 209Hodgkin Disease 198Lymphoma, Large B-Cell, Diffuse 194Lymphoma, Mantle-Cell 193Lymphoma, B-Cell, Marginal Zone 189Leukemia, Myelomonocytic, Chronic 181Leukemia, Myeloid, Chronic-Phase 171Recurrence 167Myeloproliferative Disorders 165Congenital Abnormalities 140Lymphoma, Large-Cell, Immunoblastic 132Leukemia, Myeloid, Accelerated Phase 118Blast Crisis 115Anemia, Refractory, with Excess of Blasts 114Waldenstrom Macroglobulinemia 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Primary Myelofibrosis 94Graft vs Host Disease 88Neoplasms, Plasma Cell 84

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hypercalcemia × Other hematologic neoplasm × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡